Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis - Takeaways - MDSpire

Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis

Baptist Health Brain & Spine Care is enrolling patients with confirmed multiple sclerosis who are starting BRUMVI to track outcomes, safety, and patient experience over time in a real-world setting.

  • By

  • March 4, 2026

  • 2 min

Share

  • 1

    Baptist Health Brain & Spine Care is enrolling patients with confirmed multiple sclerosis starting BRUMVI for a real-world registry study.

  • 2

    The study aims to track outcomes, safety, and patient experience of BRUMVI in everyday clinical practice.

  • 3

    Participants will share health information and complete questionnaires while continuing their usual care over 192 weeks.

  • 4

    Eligibility includes a confirmed MS diagnosis and no prior BRUMVI infusions, with specific exclusion criteria related to infections and concurrent therapies.

  • 5

    Interested patients can learn more or refer by contacting NeuroResearch@BaptistHealth.net or calling 786-596-1845.

Original Source(s)

Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis

  • by

  • March 4, 2026

Related Content

Post-streptococcal Autoimmunity and Its Relevance to Epstein–Barr virus as the Potential Cause of Multiple Sclerosis

Nuclear receptor PPARγ targets GPNMB to promote oligodendrocyte development and remyelination

Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases